Novartis is close to clinching an acquisition of Cytokinetics and its promising heart drug, as big pharma companies continue buying fast-growing biotechs to replenish pipelines.
Novartis is close to clinching an acquisition of Cytokinetics and its promising heart drug, as big pharma companies continue buying fast-growing biotechs to replenish pipelines.
Novartis is close to clinching an acquisition of Cytokinetics and its promising heart drug, as big pharma companies continue buying fast-growing biotechs to replenish pipelines.
